Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsCash from RestructuringChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyra Therapeutics (LYRA) Share-based Compensation (2021 - 2025)

Lyra Therapeutics (LYRA) has disclosed Share-based Compensation for 5 consecutive years, with $34000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Share-based Compensation fell 97.72% to $34000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $3.7 million, a 40.69% decrease, with the full-year FY2024 number at $6.7 million, up 14.08% from a year prior.
  • Share-based Compensation was $34000.0 for Q3 2025 at Lyra Therapeutics, down from $914000.0 in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $2.2 million in Q1 2024 to a low of $34000.0 in Q3 2025.
  • A 5-year average of $1.2 million and a median of $1.1 million in 2024 define the central range for Share-based Compensation.
  • Peak YoY movement for Share-based Compensation: skyrocketed 137.24% in 2022, then plummeted 97.72% in 2025.
  • Lyra Therapeutics' Share-based Compensation stood at $782000.0 in 2021, then surged by 124.68% to $1.8 million in 2022, then decreased by 15.65% to $1.5 million in 2023, then skyrocketed by 30.84% to $1.9 million in 2024, then plummeted by 98.25% to $34000.0 in 2025.
  • Per Business Quant, the three most recent readings for LYRA's Share-based Compensation are $34000.0 (Q3 2025), $914000.0 (Q2 2025), and $825000.0 (Q1 2025).